Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study

BACKGROUND: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal studies, deutetrabenazine demonstrated statistically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Barkay, Hadas, Fernandez, Hubert H., Factor, Stewart A., Jimenez-Shahed, Joohi, Gross, Nicholas, Marinelli, Leslie, Wilhelm, Amanda, Alexander, Jessica, Gordon, Mark Forrest, Savola, Juha-Matti, Anderson, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906841/
https://www.ncbi.nlm.nih.gov/pubmed/35280262
http://dx.doi.org/10.3389/fneur.2022.773999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906841/
https://www.ncbi.nlm.nih.gov/pubmed/35280262
http://dx.doi.org/10.3389/fneur.2022.773999

Ejemplares similares